Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Trial to Evaluate the Pharmacokinetics and Safety Between the Single Administration of HL1113 and the Concomitant Administration of HL1113R1 and HL1113R2 for Healthy Subjects in Fasting State
Sponsor: Hanlim Pharm. Co., Ltd.
Summary
This clinical trial is a randomized, open-label, single oral dose, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the single administration of HL1113 and the concomitant administration of HL1113R1 and HL1113R2 for healthy subjects in fasting state
Official title: A Randomized, Open-label, Single Oral Dose, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Single Administration of HL1113 and the Concomitant Administration of HL1113R1 and HL1113R2 for Healthy Subjects in Fasting State
Key Details
Gender
All
Age Range
19 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
37
Start Date
2024-10-16
Completion Date
2024-11-15
Last Updated
2026-05-06
Healthy Volunteers
Yes
Conditions
Interventions
Test group 1
* Period 1 : HL1113R1 + HL1113R2, once daily * Period 2 : HL1113, once daily
Test group 2
* Period 1 : HL1113, once daily * Period 2 : HL1113R1 + HL1113R2, once daily
Locations (1)
Central Hospital
Seoul, South Korea